Baicalein derivative as well as preparation method and application thereof

By preparing 4'-methylamine baicalein (MAB) and targeting the TLR4 protein, the problems of poor efficacy of existing antibiotics in treating sepsis and the limited application of baicalein were solved, achieving a more efficient treatment effect for sepsis.

CN118930507AActive Publication Date: 2024-11-12SHANGHAI UNIV OF T C M

Patent Information

Application Number
CN202410979206.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-12
Estimated Expiration
2044-07-22

AI Technical Summary

Technical Problem

Existing antibiotics are ineffective in treating sepsis and have drug resistance issues. Baicalein is limited in clinical application due to low bioavailability and poor solubility, and cannot effectively inhibit the inflammatory response induced by the TLR4 signaling pathway.

Method used

Develop a baicalin derivative, 4'-methylamine baicalin (MAB), prepared via a specific synthetic route for the preparation of drugs to treat sepsis, including dosage forms for sublingual, oral, transdermal, injectable, or pulmonary inhalation, targeting the TLR4 protein to inhibit the inflammatory response.

Benefits of technology

MAB significantly improved the survival rate of a mouse septic shock model induced by lethal doses of LPS, inhibited the expression of multiple cytokines, reduced damage to the body caused by excessive inflammatory response, and was non-cytotoxic with stronger TLR4 protein binding ability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930507A_ABST
    Figure CN118930507A_ABST
Patent Text Reader

Abstract

The invention discloses a baicalein derivative as well as a preparation method and application thereof. The baicalein derivative is 4 '-methylamine baicalein. Experimental results show that the MAB is low in toxicity, and compared with baicalein under the same condition, the MAB has a more remarkable inhibiting effect on excessive inflammatory reaction caused by LPS induction or pathogenic bacterium infection and has better targeted binding capacity on TLR4 protein; therefore, the MAB or at least one of the pharmaceutically acceptable salts, tautomers, stereoisomers and precursor compounds thereof is expected to be used as an active ingredient for preparing the medicine for treating sepsis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a baicalein derivative and a preparation method and application thereof, in particular to 4'-methylamine baicalein and a preparation method thereof and application thereof in preparing a drug for treating sepsis, belonging to the technical field of medicine. Background Art

[0002] Sepsis is a systemic inflammatory response syndrome (SIRS) caused by the invasion of bacteria and other pathogenic microorganisms into the human body, which can lead to shock, multiple organ dysfunction syndrome (MODS) and death. It is one of the common complications of critically ill patients and the main cause of death in critically ill patients. According to statistics, the annual incidence of sepsis has increased to about 48.9 million worldwide, of which 11 million have died, accounting for 19.70% of the world's total deaths. Sepsis is common after severe burns, infection, shock or major surgery. Its pathogenesis is complex and is closely related to pathophysiological changes in multiple systems and organs. It involves systemic inflammatory network effects, immune dysfunction, and abnormal host responses to different infectious pathogens and microbial toxins. SIRS is the main feature of sepsis, which is caused by excessive inflammatory response in the process of defending against infection and plays a key role in the pathogenesis of sepsis.

[0003] Existing studies have shown that carbapenem-resistant Klebsiella pneumoniae (CRKP) is one of the carbapenem-resistant Enterobacteriaceae (CRE), which has attracted attention due to its role in high morbidity and mortality worldwide; Gram-negative (G - ) bacteria are also the main pathogenic factor inducing sepsis. Bacterial death can release a large amount of G - Lipopolysaccharide (LPS) is the main component of the bacterial wall and can serve as the main stimulus for triggering inflammatory responses of macrophages, dendritic cells, neutrophils, etc. During sepsis, the inflammatory cascade triggered by microbial infection can lead to excessive production of cytokines, called "cytokine storm", which is considered to be the main cause of organ damage.

[0004] In addition, clinical studies have found that TLR4 is one of the earliest Toll-like receptor subtypes discovered by humans. It is widely present in tissues such as the liver, macrophages, and lungs. It can mediate the occurrence of inflammatory responses by acting on the body's inflammatory response signal transduction pathways. By inhibiting the TLR4 signaling pathway, it can inhibit inflammation in the sepsis body and alleviate the disease.

[0005] Because the current antibiotics used to treat sepsis have poor therapeutic effects and drug resistance problems, there is an urgent need to find new drugs to treat sepsis.

[0006] Baicalein is a flavonoid compound with the following chemical structure:

[0007] It is the main active ingredient extracted from the dried root of Scutellaria baicalensis Georgi, a perennial herbal Chinese medicinal plant of the Lamiaceae family. It has multiple pharmacological activities, including anti-inflammatory, antioxidant, antibacterial and anti-tumor effects. However, its direct clinical application is limited by its low bioavailability and poor solubility. Summary of the invention

[0008] In view of the above problems and needs existing in the prior art, the purpose of the present invention is to provide a baicalein derivative and a preparation method and application thereof, specifically to provide a new compound 4'-methylamine baicalein and a preparation method thereof and its application in the preparation of drugs for treating sepsis.

[0009] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0010] A baicalein derivative is 4'-methylaminobaicalein (abbreviated as MAB), having the following chemical structure:

[0011]

[0012] A preparation method of the 4'-methylamine baicalein is to adopt the following synthetic route:

[0013]

[0014] In one embodiment, the preparation method comprises the following steps:

[0015] a) dissolving the nitro-substituted cinnamic acid in a solvent and reacting it with oxalyl chloride at room temperature to obtain intermediate 2;

[0016] b) intermediate 2 and 3,4,5-trimethoxyphenol are dissolved in a solvent, and then BF3·Et2O is added to carry out reflux reaction to obtain intermediate 4;

[0017] c) dissolving intermediate 4 in a solvent, then adding iodine, and reacting at 120-150° C. to obtain intermediate 5;

[0018] d) dissolving intermediate 5 in a solvent, then adding sodium pyrosulfite to carry out reflux reaction to obtain intermediate 6;

[0019] e) dissolving intermediate 6 with potassium carbonate and methyl iodide in a solvent and then reacting at room temperature to obtain intermediate 7;

[0020] f) The intermediate 7 is added to a HI / CH3COOH solution, and then reacted at 110-130°C to obtain the compound 4'-methylamine baicalein.

[0021] In a preferred embodiment, in step a), the solvent is dichloromethane, and the molar ratio of p-nitrocinnamic acid to oxalyl chloride is 1:(1.1-1.5).

[0022] In a preferred embodiment, in step b), the solvent is toluene, and the molar ratio of intermediate 2 to 3,4,5-trimethoxyphenol is (1-1.5):1, and the molar ratio of BF3·Et2O to 3,4,5-trimethoxyphenol is (1-3):1.

[0023] In a preferred embodiment, in step c), the solvent is dimethyl sulfoxide, and the molar ratio of the intermediate 4 to the iodine element is 1:(0.1-0.5).

[0024] In a preferred embodiment, in step d), the solvent is an ethanol aqueous solution with a volume fraction of 50% to 75%, and the molar ratio of the intermediate 5 to the sodium metabisulfite is 1:(2 to 5).

[0025] In a preferred embodiment, in step e), the solvent is acetone, and the molar ratio of intermediate 6 to potassium carbonate and methyl iodide is 1:(2-5):(2-5).

[0026] One application of the 4'-methylamine baicalein is to use 4'-methylamine baicalein or at least one of its pharmaceutically acceptable salts, tautomers, stereoisomers, and precursor compounds as an active ingredient for preparing a drug for treating sepsis.

[0027] In one embodiment, the sepsis includes early sepsis, severe sepsis and septic shock.

[0028] The dosage form of the drug of the present invention is not limited, and can be a unit dosage form suitable for sublingual administration, oral administration, skin administration, injection or pulmonary inhalation, as long as it is a dosage form that can effectively allow the active ingredients to reach the body. The unit dosage form can be a common dosage form such as tablets, capsules, powders, granules, injections, oral liquids, aerosols, lozenges, or sustained-release dosage forms such as nanoformulations.

[0029] The drug of the present invention, in addition to the main active ingredient MAB, may also contain a small amount of secondary ingredients that do not affect the effective active ingredients and / or pharmaceutically acceptable carriers, for example: it may contain sweeteners to improve the taste, antioxidants to prevent oxidation, and various auxiliary materials necessary for preparations.

[0030] In addition, the definitions of terms in the present invention are as follows:

[0031] The term "pharmaceutically acceptable salt" refers to a salt formed by 4'-methylamino baicalein and a pharmaceutically acceptable inorganic acid or organic acid, wherein the inorganic acid is hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid or sulfuric acid; the organic acid is formic acid, acetic acid, propionic acid, succinic acid, 1,5-naphthalene disulfonic acid, suberic acid, oxalic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, valeric acid, diethylacetic acid, malonic acid, succinic acid, fumaric acid, pimelic acid, adipic acid, maleic acid, malic acid, aminosulfonic acid, phenylpropionic acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methanesulfonic acid, p-toluenesulfonic acid, citric acid or amino acid; the "pharmaceutically acceptable" means suitable for human use without excessive adverse side effects (such as toxicity, irritation and allergic reactions), that is, with a reasonable benefit / risk ratio.

[0032] The term "stereoisomer" refers to isomers resulting from different spatial arrangements of atoms in a molecule, such as cis-trans isomers, enantiomers, conformational isomers, and the like.

[0033] The term "precursor compound" refers to a compound that is inactive in vitro but can be converted into 4'-methylaminobaicalein by metabolism or chemical reaction in vivo, thereby exerting its pharmacological effects.

[0034] Compared with the prior art, the present invention has the following significant beneficial effects:

[0035] The experimental results of the present invention show that compared with baicalein, 4'-methylamino baicalein (MAB) can play a more significant role in protecting body temperature and improving the survival rate of severe sepsis in the mouse septic shock model induced by a lethal dose of LPS; in the inflammatory response of mouse RAW264.7 cells stimulated by LPS or heat-killed CRKP (HK-CRKP) and mouse primary peritoneal macrophages stimulated by LPS, compared with baicalein, at the same concentration, MAB can significantly inhibit the expression of cytokines such as tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), interleukin 10 (IL-10), interleukin 1β (IL-1β), chemokines (such as MCP-1, MIP-2), interferon β (IFN-β) and interleukin 10 (IL-10); and, by CETSA (Cellular Thermal Shift Assay, cell heat transfer experiment) proved that the binding ability of MAB targeting TLR4 protein is also significantly better than baicalin; thus, it can be proved that the MAB described in the present invention can reduce the damage to the body caused by excessive inflammatory response, or even death, by inhibiting the excessive inflammatory response induced by LPS or pathogen infection. In addition, the experimental results of the present invention also show that: in Raw264.7 cells, 30μM MAB acts for 24 hours without cytotoxicity and does not affect the normal proliferation of cells; in primary mouse peritoneal macrophages, 100μM MAB acts for 24 hours without cytotoxicity. Therefore, it is shown that the MAB described in the present invention or at least one of its pharmaceutically acceptable salts, tautomers, stereoisomers, and precursor compounds as an active ingredient can be used to prepare a drug for the treatment of sepsis, and the MAB described in the present invention has produced significant progress and unexpected technical effects relative to baicalin. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 The effect of MAB on the survival rate (1A) and body temperature (1B and 1C) of mice with LPS-induced septic shock is shown; in the figure: * indicates p<0.05 compared with the model group; ** indicates p<0.01 compared with the model group; *** indicates p<0.001 compared with the model group;

[0037] Figure 2 The cytotoxicity of different concentrations of MAB after co-incubation with mouse Raw264.7 cells (2A) and mouse primary peritoneal macrophages (2B) for 24 hours is shown; in the figure: ** indicates p<0.01 compared with the blank group; *** indicates p<0.001 compared with the blank group;

[0038] Figure 3 shows the effects of different concentrations of Baicalein or MAB on TNF-α ( Figure 3A)、IL-6( Figure 3B )、IL-10( Figure 3C )、MCP-1( Figure 3D )、MIP-2( Figure 3E )、IFN-β( Figure 3F ) and NO( Figure 3G ) in the figure: * indicates p<0.05 compared with the control group; ** indicates p<0.01 compared with the control group; *** indicates p<0.001 compared with the control group; ns indicates no significant difference compared with the control group;

[0039] Figure 4 shows the effects of different concentrations of Baicalein or MAB on the expression of IL-1β ( Figure 4A )、CXCL 10( Figure 4B )、iNOS( Figure 4C ) and COX-2mRNA( Figure 4D ) in the figure: * indicates p<0.05 compared with the control group; ** indicates p<0.01 compared with the control group; *** indicates p<0.001 compared with the control group; ns indicates no significant difference compared with the control group;

[0040] Figure 5 shows the effects of different concentrations of Baicalein or MAB on TNF-α ( Figure 5A )、IL-6( Figure 5B )、IL-10( Figure 5C )、MCP-1( Figure 5D )、MIP-2( Figure 5E )、IFN-β( Fig. 5F ) and NO( Figure 5G ) in the figure: * indicates p<0.05 compared with the control group; ** indicates p<0.01 compared with the control group; *** indicates p<0.001 compared with the control group; ns indicates no significant difference compared with the control group;

[0041] Figure 6 shows the effects of different concentrations of Baicalein or MAB on the expression of IL-1β ( Fig. 6A )、CXCL 10( Figure 6B )、iNOS( Figure 6C ) and COX-2mRNA( Fig.6D ) in the figure: * indicates p<0.05 compared with the control group; ** indicates p<0.01 compared with the control group; *** indicates p<0.001 compared with the control group; ns indicates no significant difference compared with the control group;

[0042] Figure 7 shows the effects of different concentrations of Baicalein or MAB on TNF-α ( Fig. 7A )、IL-6( Figure 7B )、IL-10( Figure 7C )、MCP-1( Fig.7D )、MIP-2( Fig. 7E )、IFN-β( Figure 7F ) and NO( Figure 7G ) in the figure: * indicates p<0.05 compared with the control group; ** indicates p<0.01 compared with the control group; *** indicates p<0.001 compared with the control group; ns indicates no significant difference compared with the control group;

[0043] Figure 8 shows the effects of different concentrations of Baicalein or MAB on IL-1β ( Fig. 8A )、CXCL 10( Figure 8B )、iNOS( Figure 8C ) and COX-2mRNA( Fig.8D ) in the figure: * indicates p<0.05 compared with the control group; ** indicates p<0.01 compared with the control group; *** indicates p<0.001 compared with the control group; ns indicates no significant difference compared with the control group;

[0044] Fig. 9 The targeting binding ability of MAB to TLR4 protein at different temperatures is shown; in the figure: * indicates p<0.05 compared with the DMSO group; ** indicates p<0.01 compared with the DMSO group; *** indicates p<0.001 compared with the DMSO group; # indicates p<0.05 compared with MAB and Baicalein at the same temperature. DETAILED DESCRIPTION

[0045] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer.

[0046] Example 1: Preparation of 4'-methylamine baicalin (MAB)

[0047] The following synthetic route is adopted:

[0048]

[0049] The preparation method comprises the following steps:

[0050] a) Dissolve nitro-substituted cinnamic acid 1 (6.7 g, 34 mmol) in 100 mL of dichloromethane (DCM) solvent, add oxalyl chloride (6.6 g, 51 mmol) dropwise under ice bath conditions, remove the ice bath after the addition is complete, and react at room temperature. When TLC detects that the reaction is complete (about 3 hours), concentrate the solvent to dryness, and the resulting yellow-white solid is intermediate 2;

[0051] b) The obtained intermediate 2 and 3,4,5-trimethoxyphenol 3 (6 g, 33 mmol) were dissolved in 100 mL of toluene, and then 20 mL of BF3·Et2O was added, and the reaction was stirred at reflux temperature. When the reaction was completed by TLC monitoring (about 5 hours), the reaction solution was slowly added to an ice-water mixture and stirred for 30 min, and extracted with ethyl acetate (EA) 3 times to obtain an organic phase, and then the organic phase was washed twice with a saturated NaCl solution, dried over anhydrous Na2SO4, filtered, and dried under reduced pressure to obtain an intermediate 4;

[0052] c) The obtained intermediate 4 (5.6 mmol) was dissolved in 15 mL of dimethyl sulfoxide (DMSO), and then iodine (142 mg, 0.56 mmol) was added, and the mixture was reacted at 130° C. After the reaction was completed by TLC (about 3 hours), the reaction solution was cooled to room temperature, and then 300 mL of water was added, and a large amount of solid was precipitated. After the solid was precipitated, an aqueous sodium thiosulfate solution was added to remove excess iodine, and then the mixture was stirred at room temperature for half an hour and filtered. The filter cake was washed with water, dried, and then chromatographed on a silica gel column to obtain an intermediate 5;

[0053] d) The intermediate 5 (2 g, 5.6 mmol) was dissolved in 50 mL of 65% ethanol aqueous solution, and then sodium metabisulfite (3.2 g, 16.8 mmol) was added for reflux reaction. After reflux reaction for 2 hours, 4 mL of concentrated hydrochloric acid was added and the reaction was continued for 1 hour. Then water was added to terminate the reaction, and the pH was adjusted to 8-9 with ammonia water. The organic phase was extracted 3 times with DCM, and the organic phase was washed twice with a saturated NaCl solution, dried over anhydrous Na2SO4, filtered, and dried under reduced pressure to obtain the intermediate 6;

[0054] e) intermediate 6 (1 g, 3 mmol) was dissolved in 10 mL of acetone with potassium carbonate (412 mg, 3 mmol) and iodomethane (426 mg, 3 mmol), and the mixture was reacted at room temperature for 8 hours, and then water was added to terminate the reaction. The organic phase was extracted with dichloromethane (DCM), and then the organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered, and spin-dried to obtain a crude product, which was finally purified by column chromatography to obtain intermediate 7;

[0055] f) The intermediate 7 (500 mg, 1.47 mmol) was added to 10 mL of HI / CH3COOH solution, and then reacted at 110°C. When the reaction was completed by TLC (about 18 hours), the mixture was cooled to room temperature and carefully poured into crushed ice, and then 20% sodium thiosulfate (5 mL) was added. After stirring for 30 minutes, the precipitate was collected by filtration and finally recrystallized from ethanol to obtain the target compound 4'-methylamine baicalin.

[0056] 1 H NMR (600MHz, DMSO-d6) δ7.81 (d, J = 8.5 Hz, 2H), 6.87 (s, 1H), 6.71 (d, J = 8.6 Hz, 2H), 6.67 (s, 1H), 3.91 (s, 3H).

[0057] 13 C NMR (101MHz, DMSO-d6) δ182.38,164.99,154.53,152.72,149.92,146.74,130.20,128.54,117.59,114.26,105.32,101.06,91.45,56.69.

[0058] ESI-MS: M=299.08; found m / z=300.0862.

[0059] Example 2: Investigating the effects of MAB on the survival rate and body temperature of mice with LPS-induced septic shock

[0060] 1) Sample preparation

[0061] The required amount of baicalein and 4'-methylamine baicalein (MAB) was weighed and dissolved with 3% dimethyl sulfoxide (DMSO), and diluted to 4 mg / mL with sterile saline; the positive control drug dexamethasone sodium phosphate injection (DXM) was diluted to 0.5 mg / mL with PBS; 12.5 mg / kg of lipopolysaccharide (LPS) was used to induce a septic shock mouse model.

[0062] 2) Experimental methods

[0063] Construction of mouse septic shock model: 7-week-old female C57BL / 6J mice that had been adaptively raised for 1 week were evenly distributed to each group according to their body weight and recorded with ear tags.

[0064] Grouping: LPS group, LPS+Baicalein (20 mg / kg), LPS+Baicalein (40 mg / kg), LPS+MAB (20 mg / kg), LPS+MAB (40 mg / kg) and LPS+DXM (5 mg / kg) group, a total of 6 groups, 11 mice in each group.

[0065] On the day of modeling, LPS was diluted with sterile PBS to the experimental concentration. According to the preliminary experiment, the optimal lethal concentration was 12.5 mg / kg. It was injected intraperitoneally to construct a mouse septic shock model, and drugs were injected at the same time. The living conditions and survival of the mice were observed continuously for 120 hours.

[0066] 3) Measurement and statistical methods

[0067] The survival status and survival conditions of mice in each group were recorded and observed for 5 consecutive days. The survival curves were drawn using Graphpad prism 9 software, and the Log-Rank test was used for survival analysis.

[0068] 4) Experimental results

[0069] The experimental results are as follows Figure 1 As shown by Figure 1 The results shown are as follows: ① LPS at a dose of 12.5 mg / kg can successfully induce a septic shock mouse model, with 80% of the mice in the model group dying within 40 hours, and the mice showed symptoms such as lethargy, tremors, erect hair and chills during the experiment; ② After treating septic shock mice with 20 mg / kg and 40 mg / kg of Baicalein, the survival rates were 0 and 20%, respectively; ③ MAB at 20 mg / kg and 40 mg / kg can effectively protect septic shock mice, with survival rates of 30% and 65%, respectively, which are statistically significant compared with the LPS model group; ④ The positive drug DXM can effectively protect septic shock mice, with a survival rate of 90%, which is statistically significant compared with the LPS model group; ⑤ Compared with 20 mg / kg of Baicalein, 20 mg / kg of MAB can more effectively protect septic shock mice; ⑥ 40 mg / kg of MAB can reduce the body temperature of LPS-induced septic shock model mice, which is beneficial for them to maintain or restore normal body temperature.

[0070] The above experimental results show that MAB has a protective effect on LPS-induced septic shock model mice, can prolong the survival of mice and maintain the body temperature of mice, and compared with baicalin under the same conditions, the effect is significant.

[0071] Example 3: Investigating the regulatory effect of MAB on LPS-induced inflammatory response in Raw264.7 cells of mice and primary peritoneal macrophages of mice

[0072] 1) Sample preparation

[0073] Baicalein or MAB was dissolved in dimethyl sulfoxide (DMSO) to a 50 mmol / L storage solution, and further diluted with serum-free DMEM cell culture medium to form sample solutions with gradient concentrations of 0, 3, 10 and 30 μmol / L; 100 ng / mL lipopolysaccharide (LPS) was used as a stimulator for cell-level experiments.

[0074] 2) Experimental methods

[0075] ①Cell culture of mouse macrophage cell line Raw264.7

[0076] The cells were cultured in a cell culture incubator at 37°C and 5% CO2 using DMEM high-glucose medium containing 10% fetal bovine serum (FBS). When the cell confluence reached 80%, the cells were passaged at a ratio of 1:4-1:5. The cells were gently scraped off with a cell scraper to disperse cell clumps, or the cells were counted and plated.

[0077] ② Culture of primary mouse peritoneal macrophages

[0078] SPF-grade C57BL / 6J female mice (6-8 weeks old) were intraperitoneally injected with a sterile 3.5% sodium thioglycolate solution, 1 mL / mouse per each abdomen; after 3.5 days, the mice were killed by cervical dislocation and soaked in 75% alcohol for 5 minutes; the abdominal skin of the mice was cut open, and the abdominal cavity was flushed twice with a 20mL syringe filled with pre-warmed sterile DMEM, and the flushing fluid was collected in a sterile 50mL centrifuge tube, repeatedly aspirated and blown, centrifuged at 1000rpm for 5 minutes, the supernatant was discarded, and the solution was resuspended with 10% FBS DMEM medium, diluted and counted, and then plated; after routine culture for 2 hours, the medium was changed, and the adherent cells were primary peritoneal macrophages.

[0079] ③Cell proliferation / toxicity assay

[0080] After different concentrations of MAB were co-incubated with mouse Raw264.7 cells or mouse primary peritoneal macrophages, 10 μL of CCK8 enhanced solution was added to each well according to the CCK-8 kit instructions. After adding the reagent, the culture plate was gently shaken to help mix. The cells were incubated in the incubator for 1 hour, and the absorbance at 450 nm was measured with a microplate reader. The cell viability was calculated as follows:

[0081] Cell survival rate = [(As-Ab) / (Ac-Ab)] × 100%

[0082] Where As is the absorbance of the drug test well; Ac is the absorbance of the negative control well; Ab is the absorbance of the blank well.

[0083] ④ Enzyme-linked immunosorbent assay (ELISA)

[0084] Refer to the operating steps in the instructions of the kit:

[0085] The capture antibody was diluted to the working concentration with PBS, coated on the ELISA plate, 100 μL / well, and allowed to stand at room temperature overnight; the capture antibody was discarded, and 300 μL of wash buffer (PBS containing 0.05% Tween 20, pH 7.2-7.4) was added to each well with a spray gun. After 1 minute, the wash buffer was patted dry on a paper plate, and the plate was washed 3 times. After patting dry, 300 μL / well of reagent diluent (PBS with 1% BSA, pH 7.2-7.4) was added, and the plate was blocked at room temperature for 1 hour; the reagent diluent was discarded, and the plate was washed 3 times with the above-mentioned wash buffer (the same below), and 100 μL / well of the standard and the sample to be tested was added, and incubated at room temperature for 2 hours; the sample to be tested was discarded, the plate was washed 3 times, and 100 μL / well of the detection antibody was added, and the plate was incubated at room temperature for 2 hours; the detection antibody was discarded, the plate was washed 3 times, and HRP was added 100 μL / well, incubate at room temperature in the dark for 20 min; discard HRP and wash the plate 3 times, add AB solution, incubate at room temperature in the dark for 20 min; add 50 μL / well of stop solution, detect the OD value at 450nm (detection wavelength) / 570nm (correction wavelength) with a microplate reader, and calculate the corresponding protein concentration according to the standard curve.

[0086] ⑤ Determination of nitric oxide (NO) content by Griess method

[0087] Follow the steps in the kit instructions: a) All reagents were prepared as required and preheated at 37°C for 5 min. In a 96-well plate, reagent 1 (5 μL), reagent 2 (10 μL), and reagent 3 (5 μL) were added to the sample wells, standard wells, and blank wells. Samples (cell culture supernatant), standards, and distilled water were added at 60 μL / well, mixed, and reacted at 37°C for 60 min; b) Reagent 4 was added to each well at 20 μL / well and reacted at 37°C for 30 min; c) Reaction mix was added to each well at 100 μL / well and reacted at 37°C in the dark for 15 min. The NO content in the cell supernatant was determined by an ELISA reader at 530 nm.

[0088] ⑥RNA extraction and real-time quantitative PCR analysis (qRT-PCR)

[0089] Total RNA was extracted from cells according to the kit instructions, and 0.5 μg of total RNA sample was reverse transcribed into complementary DNA (cDNA) in a total volume of 10 μL, including 5 μL SYBR, 2.2 μL RNase free ddH2O, 0.4 μL forward primer, 0.4 μL reverse primer and 2 μL cDNA, and the PCR was performed on the LightCycler fluorescence quantitative PCR system. β-Actin was used as an internal reference, and 2-ΔΔCt Methods Data analysis.

[0090] 3) Measurement and statistical methods

[0091] The experimental results of each group were statistically analyzed by one-way analysis of variance (ANOVA) using SPSS27.0 software, and the data were expressed as mean ± standard error (SEM).

[0092] 4) Experimental results

[0093] Figure 2 The cytotoxicity of different concentrations of MAB after incubation with mouse Raw264.7 cells (2A) and mouse primary peritoneal macrophages (2B) for 24 h is shown; Figure 2 As shown, in Raw264.7 cells, 0-30 μM MAB had no cytotoxicity within 24 hours and did not affect the normal proliferation of cells; in primary mouse peritoneal macrophages, 0-100 μM MAB had no cytotoxicity within 24 hours.

[0094] Figure 3 shows the regulatory effects of different concentrations of Baicalein or MAB on TNF-α(3A), IL-6(3B), IL-10(3C), MCP-1(3D), MIP-2(3E), IFN-β(3F) and NO(3G) in LPS-stimulated mouse RAW264.7 cells; As shown in Figure 3, it can be seen that in Raw264.7 cells, compared with baicalein, at the same concentration, the intervention of MAB can better inhibit the secretion of TNF-α, IL-6, IL-10, MCP-1, MIP-2, IFN-β and NO produced by LPS stimulation, and shows an obvious dose-dependent relationship.

[0095] Figure 4 shows the regulatory effects of different concentrations of Baicalein or MAB on IL-1β (4A), CXCL 10 (4B), iNOS (4C) and COX-2 mRNA (4D) in LPS-stimulated mouse RAW264.7 cells; As shown in Figure 4, it can be seen that in Raw264.7 cells, compared with baicalein, at the same concentration, MAB can significantly inhibit the expression of IL-1β, CXCL10, iNOS and COX-2 mRNA produced by LPS stimulation.

[0096] Figure 5 shows the regulatory effects of different concentrations of Baicalein or MAB on TNF-α(5A), IL-6(5B), IL-10(5C), MCP-1(5D), MIP-2(5E), IFN-β(5F) and NO(5G) in mouse primary peritoneal macrophages stimulated by LPS; As shown in Figure 5, it can be seen that in mouse primary peritoneal macrophages, compared with baicalein, at the same concentration, the intervention of MAB can better inhibit the secretion of TNF-α, IL-6, IL-10, MCP-1, MIP-2, IFN-β and NO produced by LPS stimulation, and shows an obvious dose-dependent relationship.

[0097] Figure 6 shows the regulatory effects of different concentrations of Baicalein or MAB on IL-1β (6A), CXCL 10 (6B), iNOS (6C) and COX-2 mRNA (6D) in mouse primary peritoneal macrophages stimulated by LPS; As shown in Figure 6, it can be seen that in mouse primary peritoneal macrophages, compared with baicalein, at the same concentration, MAB can significantly inhibit the expression of IL-1β, CXCL 10, iNOS and COX-2 mRNA produced by LPS stimulation.

[0098] The above experimental results show that compared with baicalein, MAB can more significantly inhibit the levels of inflammatory factors and chemokines in LPS-induced Raw264.7 cells and mouse primary peritoneal macrophages, and has a significant anti-inflammatory regulatory effect.

[0099] Example 4: Investigating the regulatory effect of MAB on the inflammatory response of mouse Raw264.7 cells induced by heat-killed CRKP (HK-CRKP)

[0100] 1) Sample preparation

[0101] Baicalein or MAB was dissolved in dimethyl sulfoxide (DMSO) to a 50 mmol / L stock solution, and further diluted with serum-free DMEM cell culture medium to form sample solutions with gradient concentrations of 0, 3, 10, and 30 μmol / L.

[0102] 2) Strain recovery and cultivation

[0103] Take out a CRKP (HS11286) glycerol tube from the -80℃ refrigerator, pick up a small amount of bacterial solution with a sterile inoculation loop and inoculate it on the LB agar plate according to the three-zone streak method, then place it in a 37℃ constant temperature incubator and invert it for 14 hours, and then store it in a 4℃ refrigerator for use.

[0104] 3) Preparation of HK-CRKP bacterial solution

[0105] Pick a single colony and place it in a shaking tube containing 2mL LB liquid culture medium, place it in a 37℃ bacterial shaker and incubate it at 250rpm for 12h, and measure the absorbance at a wavelength of 600nm to determine the concentration of the bacterial solution. After the measurement, place the bacterial solution in a water bath at 65℃ for heat inactivation for 45min. After the inactivation, centrifuge the bacterial solution at 4400rpm for 15min, discard the supernatant, and add 1mL DMEM to resuspend the bacterial solution. The concentration of the bacterial solution at this time is the measured bacterial solution concentration, where the Raw264.7 cell seed plate density is 2.5×10 5 cells / well, and the required bacterial concentration was calculated based on the number of infected cells with MOI=10 (i.e., one cell was infected with 10 bacteria).

[0106] 4) Measurement and statistical methods

[0107] The experimental results of each group were statistically analyzed by one-way analysis of variance (ANOVA) using SPSS27.0 software, and the data were expressed as mean ± standard error (SEM).

[0108] 5) Experimental results

[0109] Figure 7 shows the regulatory effects of different concentrations of Baicalein or MAB on TNF-α(7A), IL-6(7B), IL-10(7C), MCP-1(7D), MIP-2(7E), IFN-β(7F) and NO(7G) in HK-CRKP-stimulated mouse Raw264.7 cells; As shown in Figure 7, it can be seen that in Raw264.7 cells, compared with baicalein, at the same concentration, MAB intervention can better inhibit the secretion of TNF-α, IL-6, IL-10, MCP-1, MIP-2, IFN-β and NO stimulated by HK-CRKP, and shows an obvious dose-dependent relationship.

[0110] Figure 8 shows the regulatory effects of different concentrations of Baicalein or MAB on IL-1β (8A), CXCL 10 (8B), iNOS (8C) and COX-2 mRNA (8D) in HK-CRKP-stimulated mouse RAW264.7 cells; As shown in Figure 8, it can be seen that in Raw264.7 cells, compared with baicalein, at the same concentration, MAB can significantly inhibit the expression of IL-1β, CXCL 10, iNOS and COX-2 mRNA produced by HK-CRKP stimulation.

[0111] The above experimental results show that compared with baicalein, MAB can more significantly inhibit the levels of inflammatory factors and chemokines in Raw264.7 cells induced by HK-CRKP, and has a significant anti-inflammatory regulatory effect.

[0112] Example 5: Cellular Thermal Shift Assay (CETSA)

[0113] 1) Wash a whole dish of RAW264.7 cells three times with pre-cooled PBS, scrape off the cells with a cell scraper (or blow them off gently), and centrifuge at 1000 rpm for 5 min;

[0114] 2) Discard the supernatant, add 1 ml of M-PER lysis buffer (containing PMSF and protease inhibitors) to the cell pellet, resuspend, and place on ice for 30 min;

[0115] 3) Centrifuge at 4°C, 20,000 g for 20 min, collect the supernatant, and add PMSF again;

[0116] 4) Divide the supernatant into 3 equal parts;

[0117] 5) Solvent (DMSO) and MAB / Baicalein (200 μM) were added to the two tubes respectively. The volume of the solvent and drug was equal. Both were rotated at room temperature for 30 min.

[0118] 6) Each tube was divided into 12 equal parts, and then the temperature was set to 38, 42, 46, 50, 54, 58, 62, 66, 70, 74, 78 and 82°C according to the gradient. After heating in a metal bath, the mixture was placed in the bath for 3 minutes, and then taken out and immediately placed on ice;

[0119] 7) Centrifuge at 4°C, 20,000 g for 20 min;

[0120] 8) Aspirate the supernatant, add loading medium and freeze at -20℃. Do not denature it again.

[0121] Fig. 9 The targeting ability of MAB to TLR4 protein at different temperatures is shown. Fig. 9 As shown, the targeting binding ability of MAB to TLR4 protein is significantly better than that of baicalin.

[0122] In summary, it can be seen that the MAB described in the present invention is not only low in toxicity, but also has a more significant inhibitory effect on excessive inflammatory response induced by LPS or pathogen infection compared to baicalein under the same conditions, and has better targeting binding ability to TLR4 protein; therefore, it is expected that the MAB described in the present invention or at least one of its pharmaceutically acceptable salts, tautomers, stereoisomers, and precursor compounds can be used as an active ingredient to prepare a drug for the treatment of sepsis; the MAB described in the present invention has produced significant progress and unexpected technical effects compared to baicalein.

[0123] Finally, it should be pointed out that the above are only some preferred embodiments of the present invention and should not be construed as limiting the scope of protection of the present invention. Some non-essential improvements and adjustments made by those skilled in the art based on the above contents of the present invention all fall within the scope of protection of the present invention.

Claims

1. A baicalein derivative, characterized in that: It is 4'-methylamine baicalein, which has the following chemical structure:

2. A method for preparing the baicalein derivative according to claim 1, characterized in that: The following synthetic route is adopted:

3. The preparation method according to claim 2, characterized in that: The steps include: a) dissolving the nitro-substituted cinnamic acid in a solvent and reacting it with oxalyl chloride at room temperature to obtain intermediate 2; b) intermediate 2 and 3,4,5-trimethoxyphenol are dissolved in a solvent, and then BF3·Et2O is added to carry out reflux reaction to obtain intermediate 4; c) dissolving intermediate 4 in a solvent, then adding iodine, and reacting at 120-150° C. to obtain intermediate 5; d) dissolving intermediate 5 in a solvent, then adding sodium pyrosulfite to carry out reflux reaction to obtain intermediate 6; e) dissolving intermediate 6 with potassium carbonate and methyl iodide in a solvent and then reacting at room temperature to obtain intermediate 7; f) The intermediate 7 is added to HI / CH3COOH solution, and then reacted at 110-130°C to obtain the compound 4'-methylamine baicalein.

4. The preparation method according to claim 3, characterized in that: In step a), the solvent is dichloromethane, and the molar ratio of p-nitrocinnamic acid to oxalyl chloride is 1:(1.1-1.5).

5. The preparation method according to claim 3, characterized in that: In step b), the solvent is toluene, and the molar ratio of intermediate 2 to 3,4,5-trimethoxyphenol is (1-1.5):1, and the molar ratio of BF3·Et2O to 3,4,5-trimethoxyphenol is (1-3):

1.

6. The preparation method according to claim 3, characterized in that: In step c), the solvent is dimethyl sulfoxide, and the molar ratio of the intermediate 4 to the iodine element is 1:(0.1-0.5).

7. The preparation method according to claim 3, characterized in that: In step d), the solvent is an ethanol aqueous solution with a volume fraction of 50% to 75%, and the molar ratio of the intermediate 5 to the sodium metabisulfite is 1:(2 to 5).

8. The preparation method according to claim 3, characterized in that: In step e), the solvent is acetone, and the molar ratio of intermediate 6 to potassium carbonate and methyl iodide is 1:(2-5):(2-5).

9. A use of 4'-methylamine baicalein according to claim 1, characterized in that: 4'-methylamine baicalein or at least one of its pharmaceutically acceptable salts, tautomers, stereoisomers and precursor compounds is used as an active ingredient for preparing a drug for treating sepsis.

10. The use according to claim 9, characterized in that: The sepsis includes early sepsis, severe sepsis and septic shock.

Citation Information

Patent Citations

  • Application of baicalein in preparation of drug with anti-endotoxin activity

    CN105326827A

  • Scutellarein derivative as well as preparation method and application of scutellarein derivative

    CN107501222A

  • Baicalein derivative as well as preparation method and application thereof

    CN111057035A

  • Baicalein derivative, preparation method thereof and application of baicalein derivative as pancreatic lipase inhibitor

    CN118754865A

  • 4 apos; application of-methylamine baicalein in preparation of anti-photoaging product

    CN120392734A

Cited By

  • 4 apos; application of-methylamine baicalein in preparation of anti-photoaging product

    CN120392734A